Fingolimod Hydrochloride (FTY720)

A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS.

Also Known As:

Networked: 2395 relevant articles (306 outcomes, 530 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Kappos, Ludwig: 45 articles (04/2022 - 09/2006)
2.	Brinkmann, Volker: 28 articles (01/2016 - 06/2002)
3.	Cohen, Jeffrey A: 25 articles (01/2021 - 02/2010)
4.	Ziemssen, Tjalf: 24 articles (06/2022 - 12/2013)
5.	Spiegel, Sarah: 23 articles (11/2020 - 12/2004)
6.	Hartung, Hans-Peter: 22 articles (05/2022 - 02/2010)
7.	Comi, Giancarlo: 21 articles (10/2022 - 09/2006)
8.	Alroughani, Raed: 19 articles (04/2022 - 04/2014)
9.	Butzkueven, Helmut: 19 articles (04/2022 - 04/2014)
10.	Trojano, Maria: 19 articles (02/2022 - 04/2014)

Related Diseases

1.	Multiple Sclerosis 12/01/2013 - "The efficacy of the innovative oral drug fingolimod has been proven in the largest study program in multiple sclerosis (MS) demonstrating reduced relapse and reduced disability progression in relapsing-remitting MS patients. " 03/15/2013 - "Therefore, FTY720 may be a potent therapeutic agent for not only multiple sclerosis but also other neurologic diseases associated with microglial activation." 05/01/2008 - "A recent Phase II study has demonstrated that oral FTY720 is effective in reducing disease activity in relapsing multiple sclerosis with a favorable adverse-effect profile. " 01/01/2018 - "Irrespective of baseline differences indicating a higher proportion at an advanced stage of multiple sclerosis in the real world versus RCTs, fingolimod remains effective, with a manageable safety profile." 01/01/2006 - "There is therefore a need for a new, effective, and well-tolerated treatment for multiple sclerosis and FTY720 (an orally administered immunomodulatory compound with a novel mechanism of action) is one of a number of agents being evaluated for the treatment of this disease. "
2.	Relapsing-Remitting Multiple Sclerosis 01/01/2015 - "Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis." 01/01/2020 - "Fingolimod is an effective treatment for relapsing-remitting multiple sclerosis. " 01/01/2018 - "Fingolimod is an effective treatment for active relapsing-remitting multiple sclerosis (MS). " 04/01/2021 - "Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study." 01/01/2020 - "The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis."
3.	Inflammation (Inflammations) 01/01/2020 - "The negative impacts of fingolimod on BBB integrity outweighed its beneficial effects in anti-inflammation, which resulted in the lack of improvement in endpoint outcomes at 24 h after tMCAO. " 01/15/2016 - "Administration of FTY720, a functional S1PR1 antagonist, obviously blocked cardiac SphK1/S1P/S1PR1 signaling, ameliorated chronic cardiac inflammation, and then improved cardiac remodeling and dysfunction in vivo post-MI. " 03/01/2013 - "We conclude that fingolimod treatment ameliorated cerebral inflammation, at least to some extent, by reducing the availability and subsequent brain infiltration of T-lymphocytes, which improved the short and long-term sequelae after experimental ICH in rodents." 03/01/2016 - "The purpose of this study was to assess the impact of FTY720 on inflammation and the blood-retinal barrier (BRB) in diabetic rats. " 01/01/2016 - "Overall, this study demonstrates, to our knowledge for the first time, that fingolimod may be repurposed to treat cutaneous inflammation."
4.	Neoplasms (Cancer) 04/26/2016 - "FTY720 also demonstrates a proven efficacy in multiple in vitro and in vivo cancer models, suggesting a potential therapeutic role in cancer patients. " 10/15/2011 - "As they target the metabolic profile of cancer cells rather than specific oncogenic mutations, FTY720 analogues such as AAL-149 should be effective against many different tumour types, particularly in combination with drugs that inhibit autophagy." 02/01/2014 - "The novel liposomal carrier of FTY720 demonstrated improved pharmacokinetic properties, comparable activity, and a potential platform for targeted delivery to CLL by overcoming the limited application of free FTY720 to B malignancy treatment. " 09/01/2013 - "A NB xenograft model was employed to assess the efficacy of FTY720 on tumor growth. " 04/01/2023 - "Malignancies were reported in some studies following taking Fingolimod. "
5.	Autoimmune Diseases (Autoimmune Disease) 04/01/2009 - "FTY720 has shown to be highly effective in experimental allograft models and autoimmune disease models. " 02/01/2006 - "FTY720 has been shown to be highly effective in experimental allograft and autoimmune disease models. " 12/01/2005 - "FTY720 has been shown to be highly effective in experimental allotransplantation models and autoimmune disease models. " 01/01/2017 - "FTY720, a S1P-receptor modulator, has shown to be effective in several transplant and autoimmune disease models, via modulating lymphocyte homing into secondary lymphoid organs (SLOs), and thereby reducing these cells in peripheral blood. " 01/01/2012 - "Fingolimod therefore represents the first oral drug for the treatment of this autoimmune disease of the central nervous system. "

Related Drugs and Biologics

1.	Fingolimod Hydrochloride (FTY720)
2.	Sphingosine-1-Phosphate Receptors
3.	Natalizumab (Tysabri)
4.	sphingosine 1-phosphate (sphingosine-1-phosphate)
5.	Interferons
6.	Immunologic Factors (Immunomodulators)
7.	Cytokines
8.	Immunosuppressive Agents (Immunosuppressants)
9.	Sphingosine
10.	Neuroprotective Agents

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration
3.	Transplantation
4.	Injections
5.	Kidney Transplantation